Castellví I, Elhai M, Bruni C, et al. - A retrospective multicenter observational study was conducted to evaluate the safety and effectiveness of abatacept (ABA) given in routine care to individuals with systemic sclerosis (SSc). Epidemiological data and clinical outcomes were collected. First, the frequency of adverse effects was explored. Secondly, the evolution of different organ manifestations during ABA treatment was compared. Data were collected from 6 months before the start of therapy to the last follow-up the following parameters: modified Rodnan Skin Score (mRSS), joints, lung and gastrointestinal involvement, concomitant medications, and laboratory tests. Researchers recruited a total of 27 individuals with SSc (93% females; 67% limited SSc). ABA showed a good safety profile and seems to have some impact on joint involvement and related disability in SSc patients treated in routine care.